Audited Supplier
Basic Info.
| Generic Name | Cefoperazone Sodium for Injection 1g |
| Strength | 1g |
| Packing | 10vials/box |
| Origin | China |
Component:
Cefoperazone Sodium 1g.
Character:
This product is white to yellowish crystalline powder or freeze-dried lump or powder; Odorless; Crystalline powder has moisture-inducing properties, and freeze-dried products are easy to moisture-inducing.
Indications:
It is suitable for all kinds of infections caused by sensitive bacteria, such as pneumonia and other lower respiratory tract infections, urinary tract infections, biliary tract infections, skin and soft tissue infections, septicemia, peritonitis, pelvic infection, etc. The latter two should be combined with anti-anaerobic drugs.
Usage and dosage:
It can be injected intramuscularly, intravenously or by intravenous drip. Adult dosage: general infection, 1g ~ 2g, once every 12 hours; Severe infection, once 2g ~ 3g, once every 8 hours. After hemodialysis, one dose should be supplied. The daily dose is not more than 9g for adults, but may be increased to 12g for immunocompromised patients with severe infection. Pediatric dosage: 50mg/kg ~ 200mg/kg daily, divided into 2 ~ 3 times intravenous drip.
Muscle injection was prepared with 2.8ml sterilized water for injection and 1ml 2% lidocaine injection for each 1g of medicine, the concentration of which was 250mg/ml. For patients with slow intravenous injection, add 40ml glucose and sodium chloride injection for every 1g of medicine to dissolve; For intravenous infusion, 1g ~ 2g cefoperazone was dissolved in 100ml ~ 200ml glucose and sodium chloride injection or other diluents. The final drug concentration was 5mg/ml ~ 25mg/ml, and the sodium content of each 1g of cefoperazone was 1.5mmol (34mg).
Precautions:
1. This product is also effective in treating infantile infection, but there is a lack of data in the study of premature infants and neonates.
2. Interference with diagnosis: False positives may occur when urine sugar is measured by copper sulfate method, and direct antiglobulin (Coombs) tests may be positive. Maternal application of this product before delivery, newborn this test can also be positive. There were occasional increases in alkaline phosphatase, serum alanine aminotransferase, serum aspartate aminotransferase, serum creatinine, and blood urea nitrogen.
3. In patients with liver disease and/or biliary obstruction, the half-life is prolonged (2 ~ 4 times longer in severe cases), and urine excretion of cefoperazone is increased; However, effective therapeutic concentration can still be obtained in the bile of patients with severe liver disease, biliary obstruction or renal dysfunction. Dosage should be adjusted appropriately and blood concentration monitoring should be carried out. If blood concentration monitoring is not possible, the dose should not exceed 2g per day.
4. Some patients treated with this product can cause vitamin K deficiency and hypoprothrombinemia. Bleeding time and prothrombinemia time should be monitored during medication. At the same time vitamin K1 can prevent the occurrence of bleeding.
5. Long-term use of cefoperazone can cause double infection.
6. Cross allergy: People who are allergic to any cephalosporin may also be allergic to this product.
Medication for special population:
The content of cefoperazone in milk is low, so lactating women should stop lactating when using this product.
Drug interaction:
1. When combined with aminoglycoside antibiotics (gentamicin and tobramycin), this product has a synergistic effect on some susceptible strains of Enterobacteriaceae and Pseudomonas aeruginosa.
2. This product can produce hypoprothrombinemia and thrombocytopenia, and may cause bleeding when combined with the following drugs: anticoagulant heparin, coumarin or indendione derivatives, thrombolytic drugs, nonsteroidal anti-inflammatory and analgesic drugs (especially aspirin, diflunix or other salicylic acid preparations), sulfopirione, etc.
3. The chemical structure of this product contains the side chain of methiontetrazolium, so during the application of this product, drinking alcohol or intravenous injection of ethanol-containing drugs will inhibit the activity of acetaldehyde dehydrogenase, resulting in the accumulation of acetaldehyde in the blood, and the occurrence of drowsiness, hallucinations and other disulfide like reactions. Therefore, patients should not drink alcohol, take ethanol-containing drugs orally, or receive them intravenously during medication and for 5 days after discontinuation.
4. When this product is used in combination with aminoglycoside antibiotics, it should not be injected in the same bottle, because the antibacterial activity may be affected by each other.
5. This product is contraindicated with the following injections: amikacin, gentamicin, kanamycin B, doxycycline, meclofenate, amalin, Diphenhydramine, potassium magnesium aspartate, hydroxyzine hydrochloride (antelol), procainamine, aminophylline, Prochlorazine, cytochrome C, pentazocine (analgesicin), aprotinase, etc.
